| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1296 | 2015 |
| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838-3845, 2016 | 876 | 2016 |
| Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7-13, 2018 | 852 | 2018 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 429 | 2020 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer 119 (2), 153-159, 2018 | 427 | 2018 |
| Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas JK Lee, J Lee, S Kim, S Kim, J Youk, S Park, Y An, B Keam, DW Kim, ... Journal of clinical oncology 35 (26), 3065-3074, 2017 | 414 | 2017 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ... Annals of oncology 29 (8), 1807-1813, 2018 | 349 | 2018 |
| Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study RL Ferris, R Haddad, C Even, M Tahara, M Dvorkin, TE Ciuleanu, ... Annals of Oncology 31 (7), 942-950, 2020 | 316 | 2020 |
| Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ... Breast Cancer Research 13, 1-7, 2011 | 307 | 2011 |
| Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ... The lancet Diabetes & endocrinology 9 (8), 491-501, 2021 | 284 | 2021 |
| Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ... Cancer discovery 8 (7), 812-821, 2018 | 260 | 2018 |
| Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the … B Keam, SA Im, HJ Kim, DY Oh, JH Kim, SH Lee, EK Chie, W Han, ... BMC cancer 7, 1-11, 2007 | 252 | 2007 |
| Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration CY Ock, B Keam, S Kim, JS Lee, M Kim, TM Kim, YK Jeon, DW Kim, ... Clinical cancer research 22 (9), 2261-2270, 2016 | 249 | 2016 |
| Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor TM Kim, A Song, DW Kim, S Kim, YO Ahn, B Keam, YK Jeon, SH Lee, ... Journal of Thoracic Oncology 10 (12), 1736-1744, 2015 | 229 | 2015 |
| Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial SH Lee, JK Lee, MJ Ahn, DW Kim, JM Sun, B Keam, TM Kim, DS Heo, ... Annals of Oncology 28 (2), 292-297, 2017 | 221 | 2017 |
| Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer S Kim, TM Kim, DW Kim, H Go, B Keam, SH Lee, JL Ku, DH Chung, ... Journal of Thoracic Oncology 8 (4), 415-422, 2013 | 199 | 2013 |
| Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Annals of Oncology 33 (4), 406-415, 2022 | 193 | 2022 |
| Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial MS Brose, B Robinson, SI Sherman, J Krajewska, CC Lin, F Vaisman, ... The Lancet Oncology 22 (8), 1126-1138, 2021 | 193 | 2021 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer JM Mehnert, A Varga, MS Brose, RR Aggarwal, CC Lin, A Prawira, ... BMC cancer 19, 1-9, 2019 | 184 | 2019 |
| Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study RB Cohen, JP Delord, T Doi, SA Piha-Paul, SV Liu, J Gilbert, AP Algazi, ... American journal of clinical oncology 41 (11), 1083-1088, 2018 | 184 | 2018 |
Chan-Young OckLunitDirección de correo verificada de lunit.io
